ObsEva, Ensysce Biosciences And 2 Other Stocks Under $1 Insiders Are Aggressively Buying

The Dow Jones jumped by more than 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

CLS Holdings USA

• The Trade: CLS Holdings USA, Inc. CLSH Director Ross Silver bought a total of 20,000 shares at an average price of $0.09. To acquire these shares, it cost around $1.72 thousand.
• What’s Happening: The company’s stock dropped 18% over the past month.
• What CLS Holdings Does: CLS Holdings USA Inc is a diversified cannabis company that acts as an integrated cannabis producer and retailer through its Oasis Cannabis subsidiaries in Nevada and plans to expand to other states.

ObsEva

• The Trade: ObsEva SA OBSV Director Ernest Loumaye acquired a total 4,000,000 shares at an average price of $0.11. The insider spent around $440 thousand to buy those shares.
• What’s Happening: ObsEva announced strategic reorganization to consolidate operations in Switzerland.
• What ObsEva Does: ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy.

Check This Out: Top 5 Tech Stocks That That Could Sink Your Portfolio In March

BrightRock Gold

• The Trade: BrightRock Gold Corp. BRGC Chairman/CEO Mahmood Shahsavar Jamshidi acquired a total of 52,466 shares at an average price of $0.15. To acquire these shares, it cost around $7.87 thousand.
• What’s Happening: The company’s stock dropped around 29% over the past six months.
• What BrightRock Gold Does: BrightRock Gold Corp operates in gold and silver industry in Ghana.

Don’t forget to check out our premarket coverage here

Ensysce Biosciences

• The Trade: Ensysce Biosciences, Inc. ENSC Director Bob G Gower acquired a total of 379,300 shares at an average price of $0.48. The insider spent $182.35 thousand to buy those shares.
• What’s Happening: Ensysce Biosciences announced critical step in human abuse potential study of PF614 with database lock.
• What Ensysce Biosciences Does: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs.